Tyrosine Kinase Inhibitors as Antiangiogenic Drugs in Multiple Myeloma

Tyrosine kinase inhibitors are a new class of anticancer drugs, that are capable of directly interacting with the catalytic site of the target enzyme and thereby inhibiting catalysis. Therapeutically useful tyrosine kinase inhibitors are not specific for a single tyrosine kinase, but rather they are...

Descripción completa

Detalles Bibliográficos
Autor principal: Ribatti, Domenico
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2010
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4034030/
https://www.ncbi.nlm.nih.gov/pubmed/27713297
http://dx.doi.org/10.3390/ph3041125

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4034030/
https://www.ncbi.nlm.nih.gov/pubmed/27713297
http://dx.doi.org/10.3390/ph3041125

Ejemplares similares